Celularity Inc
CELUNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M | $14.3M |
| Operating income | −$61.3M | −$38.4M | −$192.3M | −$25.6M | −$109.1M | −$151.9M |
| Net income | −$91.7M | −$57.9M | −$196.3M | $14.2M | −$100.1M | −$208.2M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M | $431.0M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M | $412.3M |
| Equity | −$38.1M | $8.8M | $41.0M | $198.9M | $99.4M | −$531.4M |
| EPS (diluted) | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-1.49 | — |
| Shares out. | 23.9M | 22.0M | 165.0M | 137.7M | 124.3M | 18.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −230.9%
- Net margin
- −345.4%
- Return on equity
- 241.0%
- Return on assets
- −85.5%
- Return on capital (ROCE)
- −230.7%
- Liabilities / assets
- 135.5%
- Debt / equity
- —
- Book value / share
- $-1.59
- Revenue growth (YoY)
- −51.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -38.41distress
- Accruals / assets
- −73.1%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Philip & Daniele Barach Family TrustActivist (13D)Apr 22, 2026
- Lincoln Alternative Strategies LlcPassive (13G)Feb 11, 2026
- Dragasac LtdActivist (13D)Jul 28, 2025
- Bristol Myers Squibb CoPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Brigido StephenOfficer — Pres., Functional Regeneration | Apr 13, 2026 | Option exercise | 821 | $0.00 |
| Haines John ROfficer — Senior Exec Vice President | Apr 13, 2026 | Option exercise | 1,641 | $0.00 |
| Hariri Robert JOfficer — Chief Executive Officer | Apr 13, 2026 | Option exercise | 3,281 | $0.00 |
| Ling Geoffrey M.D.Director | Jan 12, 2026 | Grant | 19,231 | $0.00 |
| Levien VincentDirector | Jan 12, 2026 | Grant | 28,847 | $0.00 |
| Diamandis PeterDirector | Jan 12, 2026 | Grant | 20,385 | $0.00 |
| Parks Diane L.Director | Jan 12, 2026 | Grant | 30,000 | $0.00 |
| Levien VincentDirector | Dec 29, 2025 | Grant | 125,000 | $0.00 |
| Ling Geoffrey M.D.Director | Dec 29, 2025 | Grant | 125,000 | $0.00 |
| Parks Diane L.Director | Dec 29, 2025 | Grant | 125,000 | $0.00 |
| Diamandis PeterDirector | Dec 29, 2025 | Grant | 125,000 | $0.00 |
| Parks Diane L.Director | Dec 19, 2025 | Grant | 67,416 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 373,196 | 1.3 | +35.5% |
| Apr 30, 2026 | 275,407 | 5.7 | +21.6% |
| Apr 15, 2026 | 226,425 | 14.2 | -23.1% |
| Mar 31, 2026 | 294,642 | 6.4 | -32.0% |
| Mar 13, 2026 | 433,481 | 1.0 | +40.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligationMay 28, 2026
- Entered a material agreement · New financial obligation · Modified shareholder rights · Director / officer change · Other material eventApr 21, 2026
- Entered a material agreement · Other material eventMar 10, 2026
- Director / officer changeMar 5, 2026
- Director / officer changeJan 21, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Other material eventDec 23, 2025
- Shareholder voteDec 19, 2025
- Other material eventDec 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 28, 2026
- NT 10-QMay 15, 2026
- 10-KApr 30, 2026
- 3OWNERSHIP DOCUMENTApr 24, 2026
- 3OWNERSHIP DOCUMENTApr 24, 2026
- 3OWNERSHIP DOCUMENTApr 24, 2026
- SCHEDULE 13D/AApr 22, 2026
- 8-KApr 21, 2026
- 4Apr 15, 2026
- 4Apr 15, 2026
- 4Apr 15, 2026
- SCHEDULE 13DApr 3, 2026
- NT 10-KMar 31, 2026
- 8-KMar 10, 2026
- 8-KMar 5, 2026